Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories designs and manufactures life science tools and critical quality control solutions for regulated pharmaceutical, healthcare and medical device applications. The company reports through Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics, covering indicators for sterilization and cleaning processes, protein analysis and peptide synthesis systems, calibration products and genetic analysis tools.
Recurring company news includes quarterly and fiscal-year results, segment performance commentary, regular cash dividend declarations, investor conference participation and governance updates such as leadership transitions. Updates often connect Mesa's product mix, end-market conditions, debt management and operating margins with demand from regulated life sciences customers.
Mesa Laboratories (NASDAQ:MLAB) will release fourth-quarter and full fiscal year 2026 financial results on Wednesday, May 27, 2026 at approximately 6:00 A.M. ET. The company will issue a press release covering results for the quarter and fiscal year ended March 31, 2026.
Mesa Laboratories (NASDAQ:MLAB) declared a regular quarterly dividend of $0.16 per share. The dividend is payable on June 15, 2026 to shareholders of record at the close of business on May 29, 2026. The release includes a standard forward-looking risk disclaimer.
Mesa Laboratories (NASDAQ: MLAB) announced a CEO transition: Gary Owens will step down as President and CEO effective April 12, 2026, and Dr. Siddhartha Kadia will become President and CEO and join the Board effective April 13, 2026.
Dr. Kadia brings prior CEO roles at Calibre Scientific and EAG Laboratories, leadership at Life Technologies overseeing a $2 billion business, and global life-sciences experience. The company emphasized a planned, smooth leadership transition.
Mesa Laboratories (NASDAQ:MLAB) reported 3Q26 results for the quarter ended December 31, 2025. Revenues were $65.126 million, up 3.6% year-over-year (7.2% sequential). AOI excluding unusual items rose to $17.072 million (26.2% of revenues). The company repaid $8.7 million of debt, lowering Total Net Leverage Ratio to 2.62.
Division results: SDC +6.0% organic, BPD +17.5% organic, CS -2.5% organic, CG -7.1% organic (China down ~57%, ~$1.2M).
Mesa Laboratories (NASDAQ:MLAB) declared a regular quarterly dividend of $0.16 per share. The dividend is payable on March 16, 2026 to shareholders of record at the close of business on February 28, 2026. The announcement reaffirms the company’s ongoing dividend program while reiterating standard forward-looking statement caution about risks and uncertainties that could affect future results.
Mesa Labs (NASDAQ:MLAB) announced that Gary Owens, President and CEO, and John Sakys, CFO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026.
The company will deliver a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast will be accessible via the Events & Presentations section of Mesa Labs' Investor Relations website at https://investors.mesalabs.com/, and an archived replay will be available at the same link after the presentation.
Mesa Laboratories (NASDAQ:MLAB) will release third quarter fiscal 2026 financial results on Tuesday, February 3, 2026 at approximately 8:00 A.M. Eastern Time. The company will issue a press release with the results on that date.
Mesa Laboratories (NASDAQ:MLAB) announced senior management will attend three investor conferences in November–December 2025. Gary Owens, president and CEO, and John Sakys, CFO, will hold 1x1 meetings at the Raymond James Napa Valley Small Cap Symposium on November 17, 2025, participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2025 at 12:00 p.m. GMT, and appear at the 8th Annual Evercore Healthcare Conference fireside chat on December 3, 2025 at 2:10 p.m. ET.
The Jefferies fireside chat will be available via live webcast, with a replay posted in the Events & Presentations section of Mesa Lab's Investor Relations website.
Mesa Laboratories (NASDAQ:MLAB) reported 2Q26 results for the quarter ended September 30, 2025. Total revenues $60,737 (up 5.0% year-over-year) and core organic revenues +3.7%. Operating income rose 34.7% to $4,724. Non-GAAP adjusted operating income (AOI) was $14,385 (+7.2%); excluding unusual items AOI was $15,233 (+6.1%) and AOI margin was 25.1%. Net income was $2,476 (down 27.8%). Total Net Leverage Ratio was 3.02. Company cited $3.2M annualized cost reductions (net annualized savings expected $2.3M) and plans to reinvest $0.9M into SDC starting 3Q25. Division highlights: BPD core organic +16.4%, CS +10.8%, CG core organic -3.6% with China down ~58% (~$1.7M), SDC core organic -3.2%.
Mesa Laboratories (NASDAQ:MLAB) announced it will release financial results for the second quarter of fiscal 2026 after market close on Thursday, November 6, 2025.
The company is a global designer and manufacturer of life science tools and quality control solutions for pharmaceutical, healthcare and medical device industries. Media and investors may contact Gary Owens, President and CEO, or John Sakys, CFO at +1-303-987-8000. More information is available at www.mesalabs.com.